Log inStart free trialBook a demo
Book a demoLog inStart free trial
Media Database
>
Ed Silverman

Ed Silverman

Senior Writer & Pharmalot Columnist at STAT

Contact this person
Email address
e*****@*******.comGet email address
Influence score
71
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

statnews.com

Pharma still 'falling short' in providing access to low- and middle-income countries, analysis finds

More pharma companies are tailoring their business models to focus on low-income countries. But a new analysis finds overall industry efforts remain limited.
4 days ago
statnews.com

Pharmalittle: We're reading about an Alzheimer's drug about-face, B...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved
8 days ago
statnews.com

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
8 days ago
statnews.com

Pharmalittle: We’re reading about a Merck deal, GSK cancer drug dat...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
9 days ago
statnews.com

FDA scolds Merz over ‘misleading’ Instagram posts featuring interio...

For a fifth time this year, the FDA has scolded a pharma company for misleading marketing, this time over a Merz Pharmaceutical rival to Botox.
9 days ago
statnews.com

Pharmalittle: We’re reading about an Amgen data controversy, J&J su...

A tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value on Tuesday
10 days ago
statnews.com

FDA is still struggling with a lack of inspectors, but doesn’t have...

A key reason positions haven't been filled is that they require travel that ranges from 25% to 75% of the time.
10 days ago
statnews.com

Pharmalittle: We're reading about 23andMe retrenching, AstraZeneca ...

23andMe announced it would halt efforts to develop new medicines and lay off 40% of its workforce
11 days ago
statnews.com

Johnson & Johnson sues Biden administration over payment terms for ...

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some hospitals that participate in
11 days ago
statnews.com

Pharmalittle: We're reading about GSK leaving BIO, an AbbVie schizo...

GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization
12 days ago
statnews.com

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
15 days ago